Company Overview and News
Take Two (TTWO - Free Report) is set to expand its presence in the basketball video game market with the release of NBA 2K Playgrounds 2 on Oct 16. The game will be available on PlayStation5, Xbox One, Nintendo Switch and PC for $29.99. NBA 2K Playgrounds 2 features exciting content like new playgrounds, moves and players to boost user interest in the game. Players can now showcase their skills on 10 new playgrounds from around the globe.
Interest in “Fortnite,” which has taken the videogame world by storm since its release last year, may have peaked, as data compiled by Piper Jaffray showed that viewership on streaming video platform Twitch suffered the steepest-ever monthly decline for the game.
EA TTWO ATVI
Take Two’s (TTWO - Free Report) publisher 2K along with Aspyr Media announced the availability of Sid Meier's Civilization VI from Nov 16 on Nintendo Switch. Sid Meier's Civilization VI developed by Firaxis Games was originally released in October 2016. The game, which was first released on PC, was later made available on Linux, Mac and iOS platforms. The Switch version will include additional features and latest updates along with four new game scenarios based on historical events.
EA TTWO SWCH
Take Two Interactive Software’s (TTWO - Free Report) 2K division recently announced the availability of NBA 2K19. The cover of the standard edition of the latest title of this popular franchise features Giannis Antetokounmpo and is now available for $59.99. 2K also launched an NBA 2K19 20th Anniversary Edition with LeBron James on the cover. The package includes the NBA 2K19 game, 100,000 Virtual Currency, MyTEAM cards, LeBron-themed digital items for MyPLAYERs and more for $99.
EA TTWO LB GLUU
Investors in Take-Two Interactive Software, Inc. (TTWO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $70.00 Put had some of the highest implied volatility of all equity options today.
TTWO BZH BZMD
2018-09-08 seekingalpha - 2
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
KMT DISCB DISCA LBTY TWX LCII PGR DISCK IMAX CNK WMT IT LBTYK LILAB VIAB DOV BOX NWY TSM OCFC DISC VFC UPS NWS TTWO NWSA LAMR IEP OXM JNJ WIN LILAK VZ MBUU TLRD ALV.WI FARM HD KKR AIHS RCUS SSNLF TM ZS BWB NLSN CRTO WGO KLAC ATVI TEN JMBA SUOPY KR NWS AAPL AMTD BEN LYV CCI PSDO ATUS MCD CWH VIA GJV EA EVHC CMCSA LBTYB THO LBTYA RHP HMC CASY TGT S LPL T PLAY HPQ ATEYY LILA
Wedbush analyst Michael Pachter wrote Friday that an acquisition of GameStop Inc. GME, -7.25% by a private-equity firm "may not materialize in the near term," give the company's current enterprise value of $2.2 billion, or about 7 times the company's free-cash flow. "In our view, this makes the company too expensive for many private equity firms, but it is possible that a purchaser could grow FCF by slashing opex (currently tracking to over $2.
TTWO GME ATVI
Shares of Electronic Arts Inc. EA, -1.64% are down 2.4% in Friday morning trading after several analysts lowered their price targets on the stock in the wake of the company's Battlefield V delay. The stock tumbled 9.8% in Thursday's session. "In previous quarters EA has been able to meet or exceed guidance despite delays or underperformance of AAA games," wrote Oppenheimer's Andrew Uerkwitz, referring to big-budget titles.
EA TTWO ATVI
Take Two’s (TTWO - Free Report) publisher 2K expanded its portfolio by partnering with HB Studios to publish The Golf Club 2019 Featuring PGA TOUR. HB Studios known for its “award-winning golf simulation series” has developed The Golf Club 2019 Featuring PGA TOUR a sequel to The Golf Club 2. The online multiplayer game, for the first time, allows players to experience a career mode, in addition to other new features and content.
EA TTWO RSG GLUU ATVI
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to TTWO / Take-Two Interactive Software, Inc. on message board site Silicon Investor.
|Take Two Interactive Software (TTWO: Nasdaq) taking off!||Take Two Interactive Software (TTWO: Nasdaq) taking off!||Take Two Interactive Software (TTWO: Nasdaq) taking off!|
as of ET